Bayer Schering Pharma Ag

Seattle Genetics, Inc.

Jean Mark Gnoth

Johannes-Peter Stasch

Dieter Lang

Joachim Schuhmacher

Hans-Georg Lerchen

Joachim Mittendorf

Achim Feurer

Heike Heckroth

Raimund Kast

Beatrix Stelte-Ludwig

Hartmut Schirok

Ursula Krenz

Klaus Münter

Sherif El Sheikh

Sven Golfier

Samir Bennabi

Santiago Figueroa Perez

Heimo Ehmke

The present application relates to new derivatives of monomethylauristatin F, substituted on the N terminus by a carboxyalkyl group, processes for preparing these derivatives, their use for the treatment and/or prevention of diseases and to produce medication for the treatment and/or prevention of diseases, particularly hyperproliferative and/or angiogenic disorders such as cancer disorders, for example. Such treatments can occur as monotherapies or in combination with other medication or further therapeutic measures.

N-carboxyalkyl-auristatin and the use thereof

The invention relates to heteroaryloxy-substituted phenylaminopyrimidines, to methods for the production thereof, and to the use of the same for producing medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular diseases. The inventive compounds inhibit Rho-Kinase.

Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors

Growing community of inventors

Mettmann, Germany

Jean Mark Gnoth